Product NameGLIBENCLAMIDE TABLETS
Product TypeFinished Product
ContentGlibenclamide 5 mg
Dossage formTablet 20 BLPK
Medical ClassificationEndocrine System,
Company nameAcme Generics LLP
A leading provider of CMO and R&D services to the top Indian & MNC pharmaceutical companies. The Acme group began its journey in 2005 with a bold mission of becoming a leader in the contract manufacturing space and a preferred business partner for pharmaceutical companies looking for world class capabilities and scalable operations. Guided by the founder's vision and purpose, the Acme group, over the years, has scaled new heights in the pharmaceutical value chain and today provides fully integrated contract manufacturing and development solutions to some of the top Indian and global pharmaceutical companies. These include the top 25 Indian pharmaceutical companies and 5 global MNCs. Acme strongly believes in fast growth combined with a focus on innovation and service. At present the group consists of three state-of-the-art, fast growing companies viz. Acme Formulation, Immacule and Acme Generics LLP. Powering the group are 2000+ highly skilled staff working in over 500,000 sq.ft manufacturing space across Northern India, producing 15 billion tablets, 3 billion capsules, 30 million ampoules and 12 million Lyo vials. The group has also expanded into niche segments of Oral Hormones, both Sex Hormones and Levothyroxine, along with General Injectables - Liquids and Lyophilized. In our journey over the past decade we have been audited and approved by various international regulatory agencies including UK-MHRA, EU-GMP, ANVISA, PICS, INVIMA, WHO-Geneva. Apart from this the Group also has approvals across major countries in Asia, Africa, CIS and Latin Countries. US FDA filing is planned for Sterile site and expecting FDA inspection Q1, 2019 as we continue our journey towards building a sustainable future. Acme looks to the future with ever higher goals and ambitions and with its unwavering focus on service and quality is strategically poised to grow even further in the years ahead.